Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 1/20 | 0.50 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.50 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.50 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.50 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.50 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.50 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.50 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.50 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.50 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.50 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104756 | 0.84 | RORC (0.47) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15599602 | 0.84 | BTK (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL1014625 | 0.84 | BTK (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL1014626 | 0.84 | BTK (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15599532 | 0.81 | BTK (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL16989725 | 0.81 | BTK (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL21663433 | 0.80 | PDE4B (0.51) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL29730675 | 0.80 | KDM1A (0.42) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL13419727 | 0.80 | GPR119 (0.45) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL4437152 | 0.78 | POLB (0.48) | DRD2DRD3NPC1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255110-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | ROCHE PALO ALTO LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CACNB4 3797/4885CACNA1A 3794/4885CACNA1G 4590/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CACNB4 3797/4885CACNA1A 3794/4885CACNA1G 4590/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | CACNB4 3797/4885CACNA1A 3794/4885CACNA1G 4590/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CACNB4 3797/4885CACNA1A 3794/4885CACNA1G 4590/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | CACNB4 3797/4885CACNA1A 3794/4885CACNA1G 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.